Nonmalignant Hematologic Disorders

Expert faculty review and share their insights and perspectives on key findings in nonmalignant hematologic disorders presented at the 2021 ASH Annual Meeting.

Share

Program Content

Activities

  • Hematology 2021: Nonmalignant
    Key Studies in Nonmalignant Hematology: Independent Conference Coverage of ASH 2021
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 01, 2022

    Expires: February 28, 2023

Activities

Mitapivat for SCD
Phase I Dose-Escalation Study of Mitapivat (AG-348) in Patients With Sickle Cell Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

SOLACE-kids
SOLACE-kids: Phase II Study of Crizanlizumab in Adolescents With Sickle Cell Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2021

Expires: December 14, 2022

Iptacopan for PNH
Phase II Study of Iptacopan Monotherapy for Paroxysmal Nocturnal Hemoglobinuria: A 12-Mo Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

AREG: Monitoring in aGVHD
Amphiregulin as a Monitoring Biomarker for Patients With Acute GVHD
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2021

Expires: December 14, 2022

uhCG/EGF for aGVHD
Phase II Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-threatening Acute GVHD
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

Axatilimab in cGVHD
Phase I/II Study of Anti‒CSF-1R Antibody Axatilimab in Heavily Pretreated Chronic Graft-vs-Host Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 22, 2021

Expires: December 21, 2022

Abatacept for GVHD
Abatacept for Steroid-Refractory Chronic GVHD: Results From a Phase II Clinical Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

ATLAS-INH: Fitusiran for Hemophilia A/B
ATLAS-INH: Phase III Trial of Fitusiran Prophylaxis in Patients With Hemophilia A or B With Inhibitors
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2021

Expires: December 20, 2022

Etavopivat in SCD
Exploratory Analyses From a Phase I Study of Etavopivat in Sickle Cell Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

ATLAS-A/B
ATLAS-A/B: Phase III Trial of Fitusiran, an Investigational siRNA Therapy Targeting Antithrombin, in Patients With Hemophilia A or B Without Inhibitors
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation